Verastem Oncology announced the appointment of Robert Gagnon to its Board of Directors, effective December 13, 2022. Mr. Gagnon is the Chief Financial Officer and Operating Partner at Gurnet Point Capital and the former Chief Business Officer and Chief Financial Officer at Verastem Oncology. Mr. Gagnon has more than 20 years of financial and commercial experience in heading global finance operations.

Prior to his positions at Gurnet Point Capital and Verastem Oncology, he was Chief Financial Officer at Harvard Bioscience, Inc., a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine. Prior to this, he served as Executive Vice President, Chief Financial Officer, and Treasurer at Clean Harbors, Inc. as well as Chief Accounting Officer and Controller at Biogen Idec, Inc. Earlier, he worked in a variety of senior positions at Deloitte & Touche, LLP, and Price Waterhouse Coopers, LLP. He holds an MBA from the MIT Sloan School of Management and a Bachelor of Arts degree in accounting from Bentley College.